Summary The relationship between hormone replacement treatment (HRT) and breast cancer risk was analysed using data from a case-control study conducted between June 1991 and February 1994 in six Italian centres on 2569 patients aged below 75 with histologically confirmed breast cancer and 2588 controls admitted to hospital for a wide spectrum of acute, non-neoplastic, non hormone-related diseases. Ever HRT use was reported by 7.5% of cases and 7.5% of controls, corresponding to a multivariate odds ratio (OR) of 1.2 [95% confidence interval (CI), 0.9-1.5]. The risk increased with increasing duration of use: the ORs were 1.0 for use lasting less than 1 year, 1.3 for 1-4 years and 1.5 for 5 years or more. There was no clear pattern of risk with reference to time since starting use, but the OR was significantly elevated (OR = 2.0, 95% CI 1.3 -2.9) for women who had stopped HRT within the last 10 years. No association was observed in those who had stopped HRT more than 10 years ago (OR = 1.0). The increased OR for women who had stopped HRT within the last 10 years was consistent across strata of identified covariates, and was significantly related to duration of use. This study confirms the absence of a strong association between HRT and breast cancer risk, although the risk estimate was above unity for women who had used HRT for 5 years or longer. However, the risk was significantly elevated in the short to medium term after use, particularly for long-term use. This short-term increased risk is consistent with an effect of HRT on one of the later stages of the process of breast carcinogenesis. The flattening of risk with increasing time since stopping, and hence the absence of a long-term cumulative excess in breast cancer risk after stopping HRT exposure. has relevant implications on individual risk assessment and public health.
Keywords: breast neoplasms; estrogen replacement therapy; progestational hormones; case-control studies A large number of epidemiological studies have been published on the possible relationship between hormone replacement treatment (HRT) and breast cancer risk. Although overall the evidence does not support a consistent association between ever use of HRT and subsequent breast cancer risk, several issues remain unsettled (Henderson, 1989; Mack and Ross, 1989; Steinberg et al., 1991; Mann, 1992; Brinton and Schairer, 1993) .
First, a few studies conducted on European populations have found elevated relative risks (Hunt et al., 1987; Ewertz, 1988; Bergkvist et al., 1989; La Vecchia et al., 1992) . Also, among studies from North America, where the long-term use of oestrogen replacement treatment is more frequent, most investigations have found elevated risks among long-term users (Henderson, 1989; Steinberg et al., 1991; Mann, 1992 al., 1992) : the risk estimates, in fact, tend to be generally higher in European studies (Hunt et al., 1987; Bergkvist et al., 1989; La Vecchia et al., 1992) , possibly because of the different types of preparations used. In fact, following heterogeneous prescribing patterns, synthetic oestrogens and oestrogen-progestin combinations tend to be used in Europe, while conjugated oestrogens are more commonly used in North America (Mann, 1992 (La Vecchia et al., 1986 , 1992 
Data analysis
Odds ratios (ORs) of breast cancer, and the corresponding 95% confidence intervals (CIs) for various measures of HRT use were derived using unconditional multiple logistic regression, fitted by the method of maximum likelihood (Baker and Nelder, 1978; Breslow and Day, 1980) , including (i) terms for study centre and age in quinquennia only and (ii) terms for study centre, age, education, marital status, family history of breast cancer, history of benign breast disease, parity and age at first birth, age at menarche, type of menopause and age at menopause. Table I gives the distribution of breast cancer cases and the comparison group according to age and other major identified covariates. There was no difference for marital status, but cases were more educated, tended to report earlier menarche and later menopause and were less frequently multiparous and in premenopause. They also reported later first birth and more frequently family history of breast cancer and personal history of benign breast diseases. All these factors were considered potential confounders for the HRT-breast cancer analysis, and hence were included in multiple logistic regression equations. Table II considers various measures of HRT use in the overall dataset. The same proportion of cases and controls (7.5%) reported ever HRT use; thus, the age-adjusted OR was 1.0 and the multivariate OR was 1.2 (95% CI 0.9-1.5).
Results
The risk increased with duration of use: the multivariate ORs were 1.0 for use lasting less than 1 year, 1.3 for 1-4 years and 1.5 for 5 years or more. The trend in risk was of borderline significance. There was no clear pattern of risk with time since first HRT use, since the point estimates were 1.2 for use started within 10 years, 1.3 for 10-14 years and 1.1 for 15 years or more. In contrast, when time since last use was considered, the OR was significantly elevated among women who had stopped use within the last 10 years (OR = 2.0, 95% CI 1.3-2.9), but not among those who had been stopped for 10 years or more (OR= 1.0) or among current users (OR = 0.8). (Henderson, 1989; Steinberg et al., 1991) . A cohort study, in particular, found that current use was specifically related to breast cancer risk (Colditz et al., 1990 ).
This short-term increased risk is also rted in the pattern of breast cancer risk observed after a full-time pregnancy or suggested after stopping oral contraceptive use, with a short-term elevated risk that tends to lewl off or reverse after 5-10 years (Bruzzi et al., 1988; La Vecchia et al., 1990 ). This short-term effect is consistent across strata of major identified covariates. In terms of the mulistage model of carcinogeness, this would imply that HRT has a late-stage effect on breast carcinogenesis (Day and Brown, 1980) , as on other female hormone-related neoplasns, such as endometrial cancer (La Vecchia et al., 1984) . In terms of public health implications, these results suggest that the elevated breast cancer risk is restricted to the short period after stopping use, in the absence of a long-term, and hence a cumulative, excess risk after stopping HRT use.
In this study, however, there was no excess risk for current users. If not due to chance, this may be attributable to the shorter duration in current users (who had not yet complee their period of use) or to some selection anisms, which may lead women at high risk of breast cancer to withdraw from HRT use.
Although there was no significnt interaction between exogenous oestrogen use and age at dia is, there was some suggestion of higher risk in the elderly, which is consistent with the biological decine in endogenous hormones with age (Cauley et al., 1989; Brinton and Schairer, 1993) , as well as with data from other case-control studies (Brinton et al., 1986; Wmgo et al., 1987; Palmer et al., 1991; Kaufman et al., 1991) . Along a similar line of reasoning (Brinton and Schairer, 1993) , the OR was somewhat (though not significantly) higher in women with surgical menopause than in those with natural menopause. No meaningful interactions or subgroup effect were observed with any of the other variables considel, such as family history of breast cancer, body mass index or alcohol drinking, which have been debated in the past (Brinton and Schairer, 1993) . Most of the limitations and strengths of this study are common to other hospital-based case-control studies (Mantel and Haenszel, 1959) . Thus, although this study was not population based, cases were identified in the major teaching and general hospitals of the areas under surveillance, lmiting the possibility of selection bias. Still, some selecfion bias may be related to the definition of the comparison group. For this reason, only acute conditions, unrelated to known or potential risk factors for breast cancer, or to correlates of HRT use in this population (Parazzini et al., 1993) , were included in the comparison group. Further, the hospital-based design may improve the comparability of drug recall by cases and controls, and -of specific interest to this study -the participation of cases and controls was practically complete.
The potential confounding effect of several covariates was allowed for in the analysis, but did not have an appreciable impact on any of the relative risk estimates. Indeed, the multivariate relative risk estimates were systematically higher than the age-adjusted ones, suggesting that unadjusted values were somewhat, although moderately, underestimated. Of greater concern, in the interpretation of this study, was the low prevalnc of menopausal replacement treatment in this Italian population, which not only hampered detailed analysis of subgroups and interactions, but might have concealed some residual selection mechanisms.
The small absolute numbers, particularly of users of oestrogen-progestn combinations, also precluded any meaningful inference on different types of preparations. StilL there was little indication in this dataset of association with any scific type of preparation, or combination of treatments.
These limitations and potential problems notwithstanding, it is unlikely that any selection, information or confounding bias would have led to systematic and substantial underestmation of the association between HRT and breast cancer risk. Thus, these data help to better assess the pattern of breast cancer risk for various time-related aspects of HRT use in a southern European population. In more general terms of risk asessment and implications for presription, these data indicate that there is a moderate increase in breast cancer in the short to medium term after use, but are larly reassuring for the ultimate long-term impact of HRT on breast carcinogenesis.
